Copyright
©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 623-633
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623
Table 6 Diagnostic performance of fibroblast growth factor 19 and alpha fetoprotein for differentiation of hepatocellular carcinoma cases
Cut-off point | AUC | Sensitivity | Specificity | PPV | NPV | |
FGF-19 | > 180 pg/mL | 0.98 | 100% | 90% | 90% | 100% |
AFP | > 8.2 ng/mL | 0.78 | 63.33% | 83.33% | 79.2% | 69.4% |
- Citation: Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633
- URL: https://www.wjgnet.com/1948-5182/full/v14/i3/623.htm
- DOI: https://dx.doi.org/10.4254/wjh.v14.i3.623